These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6745306)

  • 41. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.
    Kirch W; Rose I; Demers HG; Leopold G; Pabst J; Ohnhaus EE
    Clin Pharmacokinet; 1987 Aug; 13(2):110-7. PubMed ID: 2887325
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of netilmicin in renal insufficiency and haemodialysis.
    Pechere JC; Dugal R; Pechere MM
    Clin Pharmacokinet; 1978; 3(5):395-406. PubMed ID: 699461
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Vincamine concentrations in plasma and cerebrospinal fluid in patients following intravenous infusion (author's transl)].
    Siegers CP; Heiss WD; Kohlmeyer K
    Arzneimittelforschung; 1977; 27(6a):1274-7. PubMed ID: 578452
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Study of the elimination kinetics of torasemide, a novel loop diuretic, in renal insufficiency.
    Dodion L; Willems JL
    Eur J Clin Pharmacol; 1986; 31 Suppl():49-51. PubMed ID: 3780839
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of spectinomycin in volunteers with renal insufficiency.
    Kusumi R; Metzler C; Fass R
    Chemotherapy; 1981; 27(2):95-8. PubMed ID: 6451365
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of a new cephalosporin, cefotaxime (HR 756) in patients with different renal functions.
    Bergan T; Larsen EW; Brodwall EK
    Chemotherapy; 1982; 28(2):85-104. PubMed ID: 6280931
    [No Abstract]   [Full Text] [Related]  

  • 47. Relationship between pharmacokinetics and bioavailability of cefroxadine (CGP 9000) and renal function.
    Bergan T; Brodwall EK; Larsen EW
    Chemotherapy; 1983; 29(3):163-73. PubMed ID: 6872614
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.
    Kirch W; Köhler H; Berggren G; Braun W
    Clin Nephrol; 1982 Aug; 18(2):88-94. PubMed ID: 7140021
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of intravenous erythromycin.
    Welling PG; Craig WA
    J Pharm Sci; 1978 Aug; 67(8):1057-9. PubMed ID: 671237
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The concentration-dependent disposition of intravenous p-aminohippurate in subjects with normal and impaired renal function.
    Prescott LF; Freestone S; McAuslane JA
    Br J Clin Pharmacol; 1993 Jan; 35(1):20-9. PubMed ID: 8448064
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An overview of the pharmacology of intravenously administered ciprofloxacin.
    Drusano GL
    Am J Med; 1987 Apr; 82(4A):339-45. PubMed ID: 3578325
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function.
    Rieder J; Schwartz DE; Fernex M; Bergan T; Brodwall EK; Blumberg A; Cottier P; Scheitlin W
    Antibiot Chemother (1971); 1974; 18():148-98. PubMed ID: 4463825
    [No Abstract]   [Full Text] [Related]  

  • 53. Pharmacokinetics of dexrazoxane in subjects with impaired kidney function.
    Brier ME; Gaylor SK; McGovren JP; Glue P; Fang A; Aronoff GR
    J Clin Pharmacol; 2011 May; 51(5):731-8. PubMed ID: 20484616
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.
    Säwe J
    Clin Pharmacokinet; 1986; 11(2):87-106. PubMed ID: 3514045
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function.
    Arancibia A; Drouguett MT; Fuentes G; González G; González C; Thambo S; Palombo G
    Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):447-53. PubMed ID: 7141752
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Neuroprotective effects of vinpocetine in vivo and in vitro. Apovincaminic acid derivatives as potential therapeutic tools in ischemic stroke].
    Dézsi L; Kis-Varga I; Nagy J; Komlódi Z; Kárpáti E
    Acta Pharm Hung; 2002; 72(2):84-91. PubMed ID: 12498034
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine.
    Gulyás B; Halldin C; Sóvágó J; Sandell J; Cselényi Z; Vas A; Kiss B; Kárpáti E; Farde L
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1031-8. PubMed ID: 12173017
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Investigation of the possible influence of the absorption of vinpocetine with concomitant application of magnesium-aluminium-hydroxide gel.
    Lohmann A; Grobara P; Dingler E
    Arzneimittelforschung; 1991 Nov; 41(11):1164-7. PubMed ID: 1810262
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Determination of plasma and renal clearance of cefuroxime and its pharmacokinetics in renal insufficiency.
    van Dalen R; Vree TB; Hafkenscheid JC; Gimbrère JS
    J Antimicrob Chemother; 1979 May; 5(3):281-92. PubMed ID: 479064
    [No Abstract]   [Full Text] [Related]  

  • 60. [The pharmacokinetics of ciprofloxacin in patients with renal function of various degrees].
    Yu H; Wang HY; Sun ZM
    Zhonghua Nei Ke Za Zhi; 1994 Jul; 33(7):449-51. PubMed ID: 7867438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.